Latest Breaking News On - Clinical activity - Page 1 : comparemela.com

STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

STC-15 is the first METTL3 inhibitor to enter clinical development Clinical data will include safety, pharmacology, target modulation, and clinical activity CAMBRIDGE, England, May

United statesSan antonioUnited kingdomJustin moserJordi rodon ahnertKyriakos papadopoulosJosefin beate holzHonorhealth research instituteAmerican society of clinical oncologyTherapeutics ltdStorm therapeutics ltdIp groupUtokyo innovation platform co ltdFast track initiativeJustin moser at honorhealth research instituteSeroba life sciences

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesAditi shastriJustine koenigsbergJared gollobEuropean hematology associationExchange commissionMontefiore medical centerAlbert einstein college of medicineKymera therapeutics incPresent new clinical dataOngoing phaseAnnual meetingChief medical officerClinical activityTargeted protein degraderRefractory hematologic

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed /.

United statesSan diegoChristina tartagliaStern investor relations incExchange commissionAmerican society of geneFate therapeutics incKey therapeutic mechanismsClinical activityAutoimmune diseasesTissue infiltrationImmune reconstitution dataRefractoryb cell malignanciesEnrollment initiatedSystemic lupusAmerican society

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2 clinical study in patients with Angelman syndrome NOVATO, Calif., April 12, 2024 .

United statesKemia olugemoMelanie brandaburRachael elizabeth hawtinCarolyn wangJoshua higaAmerican academy of neurology meetingExchange commissionUltragenyx pharmaceutical incAnnual american academyNeurology meetingClinical activityInvestigational antisense oligonucleotidePatients with angelmanEmerging scienceProteomic profiling

Ultragenyx Pharmaceutical Inc : Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

Ultragenyx Pharmaceutical Inc : Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesCarolyn wangRachael elizabeth hawtinJoshua higaDennis riedlMelanie brandaburKemia olugemoAmerican academy of neurology meetingUltragenyx pharmaceutical incExchange commissionAnnual american academyNeurology meetingClinical activityInvestigational antisense oligonucleotidePatients with angelmanEmerging science